The indications for and limitations of bone scintigraphy in osteogenic sarcoma: a review of 55 patients.
The value of radioisotope bone scanning at the time of presentation and serially during follow-up has been evaluated in 55 patients with biopsy-proven osteogenic sarcoma. Many of the patients studied were treated with adjuvant chemotherapy. Bone metastases were detected at presentation in only one patient and in a second patient, proximal extension of the primary tumor not evident on radiographs was demonstrated by the radioisotope technique. During fellow-up, 20 patients experienced bone metastases and each had an abnormal bone scan. Eleven of these patients were asymptomatic for bone metastases at the time the scan became abnormal. Seven patients experienced bone metastases as their first site of tumor recurrence. The detection rate for soft tissue metastases was low, but the scan indicated stump recurrence in three patients. Although the yield is small, bone scanning is justified at presentation be cause the results may profoundly after the management. During follow-up, routine bone cans are indicated in all patients, whether they have symptoms or not.
D000293:Adolescent; D000328:Adult; D001859:Bone Neoplasms / Q000000981:diagnostic imaging*; D002648:Child; D011756:Diphosphates; D004164:Diphosphonates; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000000981:diagnostic imaging*; D011379:Prognosis; D011877:Radionuclide Imaging; D012189:Retrospective Studies; D013667:Technetium; D013669:Technetium Tc 99m Medronate; D016698:Technetium Tc 99m Pyrophosphate
D011756:Diphosphates; D004164:Diphosphonates; D016698:Technetium Tc 99m Pyrophosphate; D013667:Technetium; D013669:Technetium Tc 99m Medronate